Epigenica has been awarded a Proof-of-Concept grant of €150,000 to begin commercialization of a new platform technology. The ERC PoC hmqPro will focus on developing novel highly-multiplexed, quantitative biomarker profiling.
Epigenica has been awarded a Proof-of-Concept grant of €150,000 to begin commercialization of a new platform technology. The ERC PoC hmqPro will focus on developing novel highly-multiplexed, quantitative biomarker profiling.
This website uses cookies. By continuing to use this site, you accept our use of cookies.